Fairmount Funds

Plus: Lee Patterson becomes CEO of Metrion, and updates from Rondo, AffyImmune and Aspargo

Marketer of Keytruda takes rights to bifunctional molecule in class that could compete directly with its top seller

Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition

In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M

Plus: Financings for newcos Nilo, Jade, Red Queen

Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM

Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience

Plus: Spyre boosts balance sheet with $180M PIPE and Pfizer’s bispecific gains EU approval for multiple myeloma

Apogee’s $300M raise NASDAQ’s second largest IPO of the year, first significant preclinical debut on exchange since last fall

Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia